EUROPEAN HIV CLINICAL FORUM 2023

Hybrid Meeting | Rome, Italy | 7 June 2023



Program Book

virology education

AcademicMedicalEducation.com

Table of Contents

Needs Statement

Second-generation Integrase strand transfer inhibitors (INSTI) have become a preferred first-line regimen for the treatment of people living with HIV (PLWH) in most international treatment guidelines. Clinical trials, as well as real-life data have shown them to be highly effective and well-tolerated, making them an attractive option for most PLWH. Single tablet, three, and two drugs INSTI and NRTI combination pills have shown similar results in drug naïve patients and are becoming widely available.

In many countries, the now-approved second-generation INSTI cabotegravir (CAB) has entered the clinical realm as a new option. The long-acting intramuscular two-drug complete regimen of CAB with rilpivirine (RPV) administered every two months offers new opportunities for patient care.

How to best use these two and three-drug regimens in the treatment-naïve, as well as suppressed individuals requiring a regimen switch, remains a key unmet educational need for clinicians caring for PLWH. Long-acting CAB has not just impacted the HIV treatment landscape, HIV prevention is also undergoing rapid changes. Clinical trials demonstrated its superiority over oral pre-exposure prophylaxis (PrEP). Other long-acting antiretrovirals will soon be entering the realm of HIV treatment and prevention, including lenacapavir (LEN), a capsid inhibitor with oral and injectable formulations.

There is a great need to assist busy healthcare professionals (HCP) in making optimal treatment and prevention decisions. Not only do they need to decide between using single tablet two versus three-drug regimens, but now also between oral and long-acting injectable therapies. Potency, resistance, tolerability, drug-drug interactions, and quality of life must all be considered when deciding between two and three-drug regimens, as well as available injectable options.

The care of PLWH with limited treatment options (often as a result of multidrug resistance), is gaining more attention. Two key drugs for this important population - fostemsavir and ibalizumab - have now been available for a number of years, and data regarding their use are accumulating. Long-term data for fostemsavir has recently been presented showing durable results. LEN was recently approved in Europe for this indication, adding an injectable option that requires consideration.

Optimal use, as well as potential investigational uses for these drugs in other populations is a challenge for HIV-treating HCPs. Presentation of these complex data and discussion on managing these populations is urgently needed.

A vast amount of new data from both clinical trials and real-world settings are emerging at rapid rate, and need to be considered when making decisions and implementing these strategies. Dissemination of these data, and how to integrate them into optimal decisions on treatment and prevention is a top priority unmet medical educational need.

To keep up-to-date with these latest developments, there is a need for a platform that effectively informs and updates HCPs in an efficient and clinically relevant manner. Additionally, clinicians need to be able to exchange experiences and discuss with experts in the field how to optimally apply the latest insights on new drugs and new treatment and prevention strategies into their practice.

It is equally crucial that this information is tailored to local and regional needs and context of care. Regional and local circumstances may vary greatly and can impact clinicians' optimal use of these drugs and treatment strategies.

The coming years will see new opportunities available to HIV-treating clinicians. Novel treatment strategies, long-acting parenteral preparation allowing infrequent dosing, and other developments will need to be learned and understood.
Educational programs must include all these in their focus.

The European HIV Clinical Forum provides a platform to enable healthcare practitioners to stay ahead of the developments in the field to optimize the clinical management and quality of life of people living with HIV.

As the data continues to grow and evolve, clinicians must have tools to evaluate these data and their application into routine clinical care.

CME Accreditation

The **European HIV Clinical Forum 2023**, Rome, Italy, **07/06/2023-07/06/2023** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **4 European CME credits** (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of *AMA PRA Category 1 Credits™*. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Meeting Objectives

The European HIV Clinical Forum program aims to:

- Build a community of healthcare professionals devoted to providing optimal clinical care for their patients;
- Create a platform for interactive information exchange on novel treatment strategies and options;
- Translate the latest studies and research achievements into clinical guidance for the optimal management of people living with HIV.

Learning Objectives

After participating in the European HIV Clinical Forum, participants will be able to:

- Discuss the scientific rational and latest clinical data supporting novel strategies for HIV treatment and prevention;
- Explain the pros and cons of novel treatment strategies and drugs, considering the comprehensive view of care (including quality of life and healthy lifestyle);
- Analyse the needs of understudied populations such as women and the aging, and how new treatments may address these;
- Understand how to integrate novel treatment strategies into routine patient care;
- Employ new treatment options for highly treatment-experienced HIV patients.

Practical Information

Badge Policy
All registered delegates are provided with an identity badge. Please wear your badge at all times to ensure admission to the meeting. No spare badges can be issued.

Certificate of Attendance
The certificate of attendance will be sent by e-mail to participants that have successfully completed the program and filled in the post-meeting survey.

Code of Conduct
All individuals are required to observe our Code of Conduct. We do not tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. Please report any incidents to VE and AME via info@amededu.com or to one of our onsite personnel. Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.

View Code of Conduct in Full:
www.AcademicMedicalEducation.com/our-commitment-diversity-and-inclusion

Enduring Materials
Webcasts of the presentations, along with the PDF presentations will be available on: www.AcademicMedicalEducation.com shortly after the meeting, assuming we have received the speakers' permission to do so.

Feedback Form
Your feedback is very valuable to us and enables us to further improve this program. At the end of the meeting, a survey will be sent to you via e-mail. We would like to ask you to complete it.

Meeting Language
The official language of the meeting is English.

Notes
You will be able to take notes in the portal during the meeting. Any notes taken throughout the event can be exported by selecting the Export icon on the top right of your screen.

Social Media
We encourage you to post news and tweet about **#EURHCF #HIVCF** on your social media accounts during the meeting. You can either post your own tweets or retweet a message from the official @Academic_MedEdu.

Time Zones
Times are in Central European Summer Time (CEST). If you need to convert the times to your timezone, this website might be of interest to you: www.WorldTimeBuddy.com.

Venue
The **European HIV Clinical Forum 2023** will be held at the Roma Eventi Fontana Di Trevi, Rome, Italy.

Virtual Platform
OnAIR is the virtual platform that will be used for the **European HIV Clinical Forum 2023** for those attending virtually. The recordings of this meeting will be available on the virtual platform until approxamitely 3 weeks after the closure of the meeting.

Your Onsite Team

Jesper Niesen
Senior Project Manager
Jesper.Niesen@amededu.com

Michelle Wu
Project Coordinator
Michelle.Wu@amededu.com

Hadil Alkhulaifi
Junior Project Coordinator
Hadil.Alkhulaifi@amededu.com

Evita Belegri
Scientific Manager

Michiel de Groot
AV Manager

Wednesday, 7 June 2023

Central European Summer Time (CEST)

09:00	**Opening of the Meeting** **Carlo Federico Perno, MD, PhD** Pediatric Hospital Bambino Gesù, Italy **Jonathan Schapiro, MD** National Hemophilia Center, Sheba Medical Center, Israel
	Session 1: Antiretroviral Therapy 2023 - State of ART Plenary Lectures *Co-Chairs: Carlo Federico Perno and Jonathan Schapiro*
09:10	**Considerations in HIV Care for Understudied Populations (Woman, Transgender, Adolescents, Aging)** **Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS** Children's National Hospital, United States
09:30	**Update on Single Tablet Regimens: Clinical Trials and Real-World Data** **Laura Waters, MD, FRCP** Central & North West London NHS Foundation Trust, United Kingdom
09:50	**Update on Long-Acting Regimens: Clinical Trials and Real-World Data** **Georg Behrens, MD, PhD** Hannover Medical School, Germany
10:10	**Discussion**
10:25	**Coffee Break**
	Session 2: HIV Prevention in 2023 *Co-Chairs: Natella Rakhmanina and Laura Waters*
10:55	**Updates on Antiviral Options for HIV Prevention** **Darrell H. S. Tan, MD, FRCPC, PhD** St. Michael's Hospital, Canada
11:15	**Oral Versus Injectable PrEP: Pros and Cons** **Michael Brady, BM, BS, FRCP** Kings College Hospital, United Kingdom
11:35	**Clinical Case: Prevention** **José Luis Blanco, MD, PhD** Hospital Clínic Barcelona / University of Barcelona, Spain
11:55	**Discussion**
12:10	**Lunch Break**

	Session 3: Starting and Switching Antiretroviral Therapy in 2023 *Co-Chairs: Annemarie Wensing and Gary Rubin*
13:10	**Clinical Considerations in Choosing the Optimal First Line Regimen** **Miłosz Parczewski, MD, PhD** Pomeranian Medical University, Poland
13:30	**Switching ART in Suppressed Patients: When, How, and to What?** **Monica Gandhi, MD, MPH** University of California San Francisco, United States
13:50	**Clinical Case: Starting and Switching Therapy** **Gary Rubin, MD, MCFP, AAHIVS** University of Toronto, Canada
14:10	**Discussion**
14:25	**Coffee Break**
	Session 4: Planning for the Future: Optimal Care for All *Co-Chairs: Monica Gandhi and Miłosz Parczewski*
15:00	**Update on Antiviral Agents for People Living with HIV with Limited Treatment Options: Clinical Trials and Real-World Data** **Antonella Castagna, MD** Vita-Salute San Raffaele University, Italy
15:20	**Repositioning: Novel Indications and Regimens with Approved Antiretroviral Drugs** **Annemarie Wensing, MD, PhD** University Medical Center Utrecht, the Netherlands
15:40	**Roundtable Discussion - Preparing the HIV Clinic for the Coming Decade: Implementing Injectables and Care of the Aging Patient**
16:00	**Closing Remarks of the Forum** **Carlo Federico Perno, MD, PhD** Pediatric Hospital Bambino Gesù, Italy **Jonathan Schapiro, MD** National Hemophilia Center, Sheba Medical Center, Israel
16:05	**End of the Meeting**

Program Director

Jonathan Schpiro, MD

National Hemophili Center, Sheba Medical Center, Israel

Jonathan M. Schapiro, MD, has devoted his career to HIV clinical care, research and education since completing his Fellowship in Infectious Diseases and Geographic Medicine at the Stanford University School of Medicine Center For AIDS Research, Stanford CA. Dr. Schapiro Graduated from the Ben Gurion University School of Medicine and completed his Medicine Residency at the Rabin Medical Center in Israel.

Dr. Schapiro's research has focused on the causes of antiretroviral drug failure, interventions to optimize clinical care, and new drug development. His interests have include resistance and cross-resistance between drugs, associations between resistance and pharmacology, development of new antiretroviral agents with improved resistance and pharmacological profiles, the clinical utility of resistance and drug level testing, and integrating resistance assays and other diagnostics into clinical care. He has been involved in the development of advanced interpretation systems for these assays, and has worked to highlight the importance of interactions between drug exposure and resistance. Dr. Schapiro currently runs the HIV/AIDS clinic at the National Hemophilia Center in Tel Aviv, Israel.

Potential Conflict of Interest

Pfizer, Moderna, Merck, Gilead Sciences, GlaxoSmithKline, Tibotec-Janssen, Teva, Virology Education, and ViiV Healthcare

View Faculty Profile >

Local Chair

Carlo Federico Perno, MD, PhD

Pediatric Hospital Bambino Gesù, Italy

Carlo F. Perno, MD, PhD, is Professor of Clinical Microbiology at the Unicamillus University in Rome, and Director of Clinical Microbiology, Immunology and Laboratory Medicine at Bambino Gesù Pediatric Hospital, Rome, Italy.

Professor Perno gained his MD from the University of Rome in 1980, and graduated in oncology in 1983. From 1986 to 1989 he worked as Research Fellow at the National Cancer Institute, Bethesda, Maryland, USA, where he collaborated to the discovery and clinical application of the first antiviral drugs used in the therapy of HIV infection, including AZT, ddC, d4T and ddI.

Professor Perno has written hundreds of scientific publications, including peer reviewed articles in high ranking journals (Nature, Science, Lancet, PNAS, J Experimental Medicine, PNAS), mostly dedicated to HIV therapy. In 2001 the European Community awarded him the Descartes Award for excellence in the antiviral field.

He has a major expertise in antiviral therapy, clinical interpretation and therapeutic application of antiviral resistance testing.
therapy, clinical interpretation and therapeutic application of antiviral resistance testing.

No Potential Conflict of Interest to Report

View Faculty Profile >

Georg Behrens, MD, PhD

Hannover Medical School,
Germany

Prof. Georg MN Behrens is Professor for T Cell Immunology in the Department for Rheumatology and Immunology at Hannover Medical School, Hannover Germany. He graduated in medicine in 1995 and did his clinical training in Internal Medicine and Infectious Diseases. From 2001-2003, he went as a postdoc to the Immunology Division at the Walter and Eliza Hall Institute for Medical Research, Melbourne, Australia and returned to Hannover to become a professor for immunology.

Georg Behrens is an acknowledged expert in HIV Medicine and Immunology and head of HIV Medicine at Hannover Medical School. He has worked on antigen presentation by dendritic cells (e.g. cross-presentation), anti-viral immunity, autoimmunity and immune response after vaccination. His work was published in journals including Nat Med, Nat Immunol, Lancet, Lancet ID, J Clin Invest, Clin Infect Dis, AIDS, and others.

Until 2022, Georg Behrens was Chair of the EACS Treatment Guidelines and he was president of the German AIDS Society for many years. He is principal investigator of national and international studies in HIV medicine and NEAT ID Executive Member. He is chair of the MD/PhD Program "Molecular Medicine", Co-Editor of HIV Medicine and Co-chair of the HIV research group of the German Center for Infection Research.

Potential Conflict of Interest
Gilead, Janssen, MSD, ViiV

View Faculty Profile >

José Luis Blanco, MD, PhD

Hospital Clínic Barcelona/
University of Barcelona,
Spain

Jose Luis Blanco is a consultant at the HIV / AIDS Unit and Infectious Disease Service, Associate Professor University of Barcelona since 2015 and Professor del Master of AIDS University of Barcelona since 2002. He is Consultant in Charge of the Research in HIV Resistance and Rescue Therapies, Sexually Transmission Diseases Unit and Program of Anal Canal Prevention Program and he is author of more than 100 scientific articles and the principal investigator of national and international projects in the field of HIV infection and related infections.

Potential Conflict of Interest
Gilead, Janssen, MSD, Theratechnologies, ViiV

View Faculty Profile >

Michael Brady, BM, BS, FRCP

Kings College Hospital,
United Kingdom

Dr. Michael Brady is a Sexual Health and HIV consultant at Kings College Hospital in south London, in an area with the highest HIV prevalence in the UK.

He works in both HIV and sexual health outpatient clinics and has a particular interest in HIV transmission, primary HIV infection, HIV testing and prevention strategies and PrEP. He was the principal investigator on the PARTNER, PROUD and PrEP Impact studies at Kings College Hospital.

Michael is also the co-chair of the British HIV Association (BHIVA) / British Association of Sexual Health and HIV (BASHH) PrEP guideline writing group and is currently supporting work to review and update British national PrEP guidelines.

Michael was appointed as the first National Advisor for LGBT+ Health at NHS England in 2019, with the remit of reducing LGBT+ health inequalities, improving healthcare experience, access and outcomes for LGBT+ individuals and ensuring the NHS is an inclusive place to work for its LGBT+ staff.

Until September 2022, Michael was the Medical Director at the Terrence Higgins Trust, the largest HIV and Sexual Health charity in the UK.

Potential Conflict of Interest
Gilead

View Faculty Profile >

Antonella Castagna, MD

Vita-Salute San Raffaele University,
Italy

Antonella Castagna has a broad background in the management of HIV-1 infected patients and her research included the control of opportunistic infections and long-term non HIV complications (cardiovascular risk, cirrhosis, cancer, diabetes) and antiretroviral drugs, the evaluation of new therapeutic strategies aimed at reducing ART toxicity and management of multidrug-resistance as well as the evaluation of clinical implications associated with the occurrence of residual viremia. Her current research interests are in the field of HIV reservoirs and on the interventions aimed at reducing these reservoirs. In addition, she successfully administered several projects funded by national and international agencies, collaborated with other researchers, and produced several peer-reviewed publications from each project. A distinct characteristic of her work is the attention to the "clinical relevance" of the projects to ensure that, where possible, any outputs can be translated into improvements in clinical care.

Potential Conflict of Interest
Cilag, Gilead, Janssen, MSD, ViiV

View Faculty Profile >

Monica Gandhi, MD, MPH

University of California San Francisco, United States

Monica Gandhi, MD, MPH, is an Infectious Diseases doctor, Professor of Medicine and Associate Chief in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF). She is also the Director of the UCSF Center for AIDS Research (CFAR) and the Medical Director of the HIV Clinic ("Ward 86") at San Francisco General Hospital. Her research focuses on HIV and women and adherence measurement in HIV treatment and prevention and most recently, on how to mitigate the COVID-19 pandemic.

No Potential Conflict of Interest to Report

View Faculty Profile >

Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS

Children's National Hospital, United States

Dr. Natella Rakhmanina is a Professor of Pediatrics at the George Washington University and serves as a Director of the HIV Program at Children's National Hospital in Washington, DC, USA. Dr. Rakhmanina obtained her MD degree at People's Friendship University in Moscow, Russia, and her PhD degree at the Erasmus University in Rotterdam, the Netherlands. For more than 20 years she has been providing clinical care to HIV-infected infants, children and adolescents, and continues her practice treating pediatric and adolescent patients in metropolitan DC area. She is certified in HIV medicine and is a successful clinical researcher, focusing her research on the treatment and prevention of HIV in children and adolescents and serving as a principal investigator of NIH, CDC and industry funded pediatric and adolescent HIV studies. Dr. Rakhmanina is also a Senior Technical Advisor at Elizabeth Glaser Pediatrics AIDS Foundation leading several projects on pediatric and adolescent HIV treatment in Sub-Saharan African countries. Dr. Rakhmanina is a Chair of the Committee on Pediatric AIDS at the American Academy of Pediatrics, member of the US Department of Health and Human Services Panel on the Pediatric Antiretroviral Therapy and Management Guidelines at the Office of AIDS Research Advisory Council in National Institutes of Health, member of the Pediatric Advisory Working Group at the World Health Organization, and a Regent of the Board and Chair of the Bylaws committee at the American College of Clinical Pharmacology.

No Potential Conflict of Interest to Report

View Faculty Profile >

Miłosz Parczewski, MD, PhD

Pomeranian Medical University,
Poland

Miłosz Parczewski, MD, PhD, has received the MD diploma at the Pomeranian Medical University, Poland in 2002 and was granted a PhD diploma in molecular epidemiology in 2007. He is a practicing infectious diseases specialist (ID specialist diploma obtained in 2011), being currently a head and full professor at the Department of Infectious, Tropical Diseases and Acquired Immunodeficiency Pomeranian Medical University, Szczecin, Poland.

His research focuses on the molecular epidemiology in HIV infection and HCV coinfection: aspects of the genetic variability of the host with the key interest in chemokine and interleukin receptor genes, HIV genetic variability - evolution of drug resistance and tropism, phylogeographic tracing of the viral transmission and recombination. Furthermore, he investigates association between genetic HIV-1 infection susceptibility and survival and variants of the host associated with the drug adverse reactions. He is a vice-president European AIDS Clinical Society, and a president of the Polish Scientific AIDS Society.

Potential Conflict of Interest
Abbvie, Gilead, MSD, Polpharma, Roche, ViiV\GSK

View Faculty Profile >

Gary Rubin, MD, MCFP, AAHIVS

University of Toronto,
Canada

Gary Rubin is a graduate of Dalhousie University in Halifax Nova Scotia and currently Assistant Professor in the Department of Family and Community Medicine at the University of Toronto and Sunnybrook Health Sciences Center. He is the Medical Director at CW Health, a Multi Disciplinary Clinic specializing in the treatment of people living with HIV. He is a member of the Medical Advisory Boards for Gilead, Moderna, and VIIV and has been involved in many Phase II and Phase III HIV clinical trials. He is also a member of the Credentialing Committee of the American Academy of HIV Medicine. Recently he has also been a consultant on COVID-19 to major financial institutions.

Potential Conflict of Interest
Gilead, MSD, Merck, Moderna

View Faculty Profile >

Darrell H. S. Tan, MD, FRCPC, PhD

St. Michael's Hospital, Canada

Darrell H. S. Tan is an infectious diseases physician and Clinician-Scientist at St. Michael's Hospital, where he leads the Options Collaboratory in HIV/STI Treatment and Prevention Science. He is also an Associate Professor in the Department of Medicine and Institute of Health Policy, Management and Evaluation at the University of Toronto, with a cross-appointment in the Institute of Medical Science. His research focuses on clinical trials and implementation science in the areas of HIV prevention and treatment, and sexually transmitted infections (STIs). Dr. Tan holds a Tier 2 Canada Research Chair in HIV Prevention and STIs, is Co-Lead of the HIV Prevention Core of the CIHR Canadian HIV Trials Network and is a member of the Governing Council of the International AIDS Society.

Potential Conflict of Interest

Abbvie, Gilead, GSK

View Faculty Profile >

Laura Waters, MD, FRCP

Central & North West London NHS Foundation Trust, United Kingdom

Laura Waters is a HIV & Sexual consultant and HIV lead at The Mortimer Market Centre, London and an Honorary Associate Professor at The Institute of Global Health, University College London. She is the National Specialty Advisor for HIV, chairing the group that advises NHS England on HIV treatment, the immediate past chair of the British HIV Association (BHIVA) & chair of the British Association of Sexual Health & HIV (BASHH) Patient & Public Voice panel.

Laura has led or co-authored several national guidelines. She has published & presented widely, is a trustee for The Food Chain and previously for the Terrence Higgins Trust. She teaches regularly at local, regional and national level, including on HIV courses for University College London and the London School of Hygiene & Tropical Medicine. Laura founded The People First Charter in July 2021.

Potential Conflict of Interest

Gilead, Janssen, MSD, Pfizer, ViiV

View Faculty Profile >

Annemarie Wensing, MD, PhD

University Medical Center Utrecht,
the Netherlands

Annemarie M.J. Wensing, MD, PhD, is a Clinical Virologist at the University Medical Center Utrecht and a Honorary Professor at the University of the Witwatersrand in Johannesburg.

She attained her MSc and MD at the University of Utrecht. During her post graduate rotations she became involved in clinical HIV research and care. She worked at the HIV outpatient clinic of the University Medical Center (UMC) Utrecht and was subsequently trained as a clinical virologist. She obtained her PhD on Transmission of drug resistant HIV-1. She is the clinical supervisor of the HIV laboratory in the UMC Utrecht which serves as a reference laboratory for HIV resistance testing and performs resistance testing on dried blood spots send in from areas all over the world.

As consultant she advises infectious disease specialists from multiple HIV-centers in the Netherlands. Her research focuses on HIV cure and on transmission and mechanisms of HIV drug-resistance and since recently also on SARS-CoV-2 pathogenesis. She is a principal investigator of several international projects such as the IciStem program that guides and investigate a potential HIV cure by stem cell transplantation. She has served as a governing board member of the EACS, is a founding member of the European Society of Antiviral Research, a member of the WHO HIV Drug Resistance ResNet and chair of the IAS-USA resistance mutations panel.

Potential Conflict of Interest
No information received

View Faculty Profile >

Support

SUPPORTER

The **European HIV Clinical Forum 2023** is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

ENDORSERS

Notes

Notes

academic
medical education

virology
education

AcademicMedicalEducation.com